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Abstract
There is a difficulty in the molecular diagnosis of congenital adrenal hyperplasia (CAH) due to the c.955C>Tp.Q319* (p.(Q319*), formerly Q318X, rs7755898) variant of the CYP21A2 gene. Therefore, a systematic assessment of the genetic and evolutionary relationships between c.955C>Tp.Q319*, CYP21A2 haplotypes and the RCCX copy number variation (CNV) structures, which harbor CYP21A2, was performed.
In total, 389 unrelated Hungarian individuals with European ancestry (164 healthy subjects, 125 patients with non-functioning adrenal incidentaloma (NFAI) and 100 patients with classical CAH) as well as 34 adrenocortical tumor specimens were studied using a set of experimental and bioinformatic methods.
A unique, moderately frequent (2%) haplotypic RCCX CNV structure with three repeated segments, abbreviated to LBSASB, harboring a CYP21A2 with a c.955C>Tp.Q319* variant in the 3’-segment, and a second CYP21A2 with a specific c.*12C>T (rs150697472) variant in the middle segment occurred in all c.955C>Tp.Q319* carriers with normal steroid levels. The second CYP21A2 was free of CAH-causing mutations and produced mRNA in the adrenal gland, confirming its functionality and ability to rescue the carriers from CAH. Neither LBSASB nor c.*12C>T occurred in classical CAH patients. However, CAH-causing CYP21A2 haplotypes with c.955C>Tp.Q319* could be derived from the 3’-segment of LBSASB after the loss of functional CYP21A2 from the middle segment.
The c.*12C>T indicated a functional CYP21A2 and could distinguish between non-pathogenic and pathogenic genomic contexts of the c.955C>Tp.Q319* variant in the studied European population. Therefore, c.*12C>T may be suitable as a marker to avoid this genetic confound and improve the diagnosis of CAH.
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Introduction
RCCX copy number variation (CNV) is a complex (it contains another CNV), multiallelic (there are more than two frequent CNV alleles in a population) and tandem (CNV segments are next to each other) CNV ADDIN EN.CITE 1-3. Two full-length genes, complement component 4 (C4) and steroid 21-hydroxylase (CYP21) are located in RCCX CNV. C4 has two types with slightly different immune functions4, C4A and C4B, and it contains an additional CNV, HERV-K(C4) CNV, in its intron 9 (Figure 1), derived from an ancient insertion of human endogenous retrovirus. RCCX CNV in one chromosome is referred as a haplotypic structure, and is traditionally described by the copy number of the segment, and, per segment, by the types of C4 and the alleles of HERV-K(C4) CNV (see the explanation of more specialized genetic terms in Table 1). A haplotypic RCCX CNV structure usually contains one functional CYP21 gene (CYP21A2) in the 3’-segment, and zero, one or two disabled pseudogenes (CYP21A1P) in the segments towards the 5’-direction (Figure 1). CYP21A2 expresses the steroid 21-hydroxylase enzyme (cytochrome P450c21) uniquely in adrenal cortex, which is one of the enzymes responsible for the biosynthesis of the two principal steroid hormones, aldosterone and cortisol5. Aldosterone regulates blood pressure by acting on kidney functions, and cortisol suppresses immune functions, responds to stress and takes part in the intermediary metabolism of different tissues. Two chromosomal copies of disabled steroid 21-hydroxylase gene (CYP21A2) causes congenital adrenal hyperplasia (CAH; we use this broader, but more prevalent, term instead of 21-hydroxylase deficiency), an autosomal recessive disorder accompanied by a partial or complete lack of aldosterone and cortisol ADDIN EN.CITE 6. Special genetic rearrangements generally featured by multiallelic CNVs, such as non-allelic gene conversion and unequal crossover7, are responsible for the vast majority of CYP21A2 mutations leading to CAH8; therefore, the complex genetic structure of RCCX CNV indirectly manifests in CAH.
Difficulties in the molecular diagnosis of CAH due to the complicated genetic nature of RCCX CNV have been recognized for a long time9, and the best-known case for this is a LSS haplotypic RCCX CNV structure with three segments harboring two copies of CYP21A2 and the p.Q319*(c.955C>T (p.(Q319*), rs7755898) variant. (For numbering the genetic variants, we use the most recent human reference gene and the corresponding mRNA sequence (RefSeqGene NG_007941.3 and NM_000500.7) which contains the insertion (CTG) allele of the c.28_30delCTG (rs61338903) variant. Therefore, our numbering differs from the studies using a CYP21A2 sequence (for example former RefSeqGene, NG_007941.2) with the deletion allele of c.28_30delCTG. The p.(Q319*) variant name is used with parentheses at protein level according to the nomenclature recommendation of Human Genome Variation Society (http://varnomen.hgvs.org/), which considers a protein variant without experimental evidence at RNA or protein level as a predicted one, however, the segregation patterns of classical (severe form) CAH families ADDIN EN.CITE , (especially patients from consanguineous families with family history having homozygous c.955T genotypes without any other CAH mutations in exons and exon/intron boundaries and without reported duplicated CYP21A2 ADDIN EN.CITE 13) have provided clinical evidences for the pathogenicity since the initial report of c.955C>T HYPERLINK \l "_ENREF_14" \o "Globerman, 1988 #1111"  ADDIN EN.CITE <EndNote><Cite><Author>Globerman</Author><Year>1988</Year><RecNum>1111</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>1111</rec-number><foreign-keys><key app="EN" db-id="a05rzdtxgr9z5se9rab5vts7z5dd5prd95vx">1111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Globerman, H.</author><author>Amor, M.</author><author>Parker, K. L.</author><author>New, M. I.</author><author>White, P. C.</author></authors></contributors><auth-address>Division of Pediatric Endocrinology, Cornell University Medical College, New York 10021.</auth-address><titles><title>Nonsense mutation causing steroid 21-hydroxylase deficiency</title><secondary-title>J Clin Invest</secondary-title><alt-title>The Journal of clinical investigation</alt-title></titles><periodical><full-title>J Clin Invest</full-title></periodical><pages>139-44</pages><volume>82</volume><number>1</number><edition>1988/07/01</edition><keywords><keyword>Adrenal Hyperplasia, Congenital/enzymology/etiology/*genetics</keyword><keyword>Amino Acid Sequence</keyword><keyword>Base Sequence</keyword><keyword>Codon/genetics</keyword><keyword>*Genes</keyword><keyword>Humans</keyword><keyword>Molecular Sequence Data</keyword><keyword>*Mutation</keyword><keyword>Nucleic Acid Hybridization</keyword><keyword>Oligonucleotides/genetics</keyword><keyword>Steroid 21-Hydroxylase/*genetics</keyword><keyword>Steroid Hydroxylases/*genetics</keyword><keyword>Transfection</keyword></keywords><dates><year>1988</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>0021-9738 (Print)&#xD;0021-9738 (Linking)</isbn><accession-num>3267225</accession-num><work-type>Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, P.H.S.</work-type><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/3267225</url></related-urls></urls><custom2>303487</custom2><electronic-resource-num>10.1172/JCI113562</electronic-resource-num><language>eng</language></record></Cite></EndNote>14.) This unique RCCX structure was found for the first time in three patients with CAH, and the c.293-13C> R (rs6467) CAH mutation accompanied the c.955C>T variant10. The unique RCCX structure with c.955C>T and c.293-13C> R has been confirmed in a Dutch CAH population15, but the same RCCX structure without the c.293-13C> R has been observed in the healthy subjects of a Dutch population as well16. After the initial findings, several studies on the topic have been published over time. However, healthy and CAH populations have rarely been examined simultaneously, and the determination of underlying RCCX structures has often been incomplete or has not been documented (Table 2). Nevertheless, new information on the unique haplotypic RCCX structure has been accumulated. In a healthy Spanish population, two CYP21A2 gene copies in one chromosome are associated with three genetic variants in complete linkage disequilibrium (LD); c.955C>T, c.293-79G>A (rs114414746) and c.*12C>T (rs150697472) variants. They occur with a moderate allele frequency (2.77%), and c.955C>T is located in the 3’-segment of CYP21A2, while a wild-type CYP21A2 is in the middle segment17. An incomplete association among c.955C>T, c.293-79G>A and c.*12C>T has also been found in a later study ADDIN EN.CITE 18, but, unfortunately, the diagnoses of CAH in the studied individuals have not been clearly documented, and therefore it cannot be known if the presence or absence of the association has been assigned to patients with CAH or healthy subjects.
In the current study, a healthy and a CAH population with the same European ancestry were used in order to assess the occurrences and association of the haplotypic RCCX structure with three segments, two CYP21A2 in the same RCCX structure, c.955C>T, c.293-79G>A and c.*12C>T, and to offer a solution for the diagnostic problem. A recent set of experimental and bioinformatic methods ADDIN EN.CITE , were applied to decipher the exact haplotypes of RCCX structure and CYP21A2, and to translate the evolutionary origin of the studied genetic variants into clinically useful information. Furthermore, patients with non-functioning adrenal incidentaloma (NFAI), which is a hormonally inactive adrenal mass unintentionally discovered by medical imaging20, and the adrenocortical tumor specimens of NFAI patients, were used to compare blood hormone levels and to examine the mRNA levels. The rationale for studying NFAI patients was; i.) the baseline hormone profiles of NFAI subjects do not differ from those of healthy subjects, ii.) the NFAI subjects had a broader hormone profile, iii.) their tumor specimens are available.
Materials and Methods
Subjects and clinical data
For the subjects with the c.955C>T (p.Q319*) variant, 96 healthy subjects (50% women) from a family study21, 68 healthy subjects (65.2% women) and 125 patients (76.0% women) with NFAI from a recent study ADDIN EN.CITE 22, 100 patients (58.0% women) with classical CAH due to 21-hydroxylase deficiency from the 2nd Department of Internal Medicine, Semmelweis University (Budapest, Hungary) and the 2nd Department of Pediatrics, Semmelweis University (Budapest, Hungary) were screened. In addition, one patient with supposed classical CAH was referred to us by the Department of Pediatrics, University of Pecs (Pecs, Hungary) for re-examination of the original genetic diagnosis. All subjects were genetically unrelated and Hungarian with European ancestry. The exclusion criteria for NFAI patients were recently described ADDIN EN.CITE 22. The diagnosis was confirmed in all CAH patients by hormonal and genetic testing (except for the one who was reexamined) as described ADDIN EN.CITE ,. Furthermore, 34 adrenocortical tumor specimens of NFAI patients were obtained as described ADDIN EN.CITE 25, and screened for the c.955C>T variant. All subjects gave written informed consent. The study protocol was approved by the National Scientific and Ethical Committee, Medical Research Council of Hungary (TUKEB, ETT), and was executed according to the Declaration of Helsinki principles.
Genetic analyses of RCCX CNV and CYP21 genes
The c.955T allele, full haplotypic RCCX CNV structures, full-length CYP21A1P and CYP21A2 haplotypes were determined as previously described ADDIN EN.CITE ,,. Briefly, a combined molecular and inferred haplotyping approach was used with two stages. C4-type-specific quantitative PCRs (qPCR), CYP21-genes-specific qPCR, HERV-K(C4) CNV allele-specific qPCR, a set of CYP21-genes-specific nested polymerase chain reactions (PCRs) resting on a set of allele-specific long-range (ASLR) PCRs and the Sanger sequencing of the nested PCR products were carried out in the first, experimental stage. One smaller modification was set up using a new CYP21A1P-specific nested PCR primer for one individual, CYP21A1P_2R (Supplementary Table 1), because a mutation of CYP21A1P decreased the binding efficacy of the original primer, CYP21A1P_R ADDIN EN.CITE 1. The experimentally determined new CYP21A1P and CYP21A2 haplotypes are available in GenBank (www.ncbi.nlm.nih.gov/genbank/) under KU302771-KU302776 IDs, and variants (IDs in Supplementary Table 2) in dbSNP (www.ncbi.nlm.nih.gov/projects/SNP/). The above-mentioned haplotypic genetic features of RCCX CNV and CYP21 genes which could not be determined in some subjects were inferred by bioinformatic haplotype reconstruction in the second stage. To map the origin of haplotypic RCCX structures and CYP21A2 haplotypes, a genealogical haplotype network was constructed using the new and published CYP21A2 haplotypes (Supplementary Table 2 and 3) as described ADDIN EN.CITE 1.
Functional studies on CYP21A2
Total RNA was isolated from adrenocortical tumor specimens by RNeasy Lipid Tissue kit (Qiagen), cDNA was synthesized by ProtoScript II kit (New England Biolabs), and CYP21A2 mRNA level was determined by qPCR using a combined approach as described  ADDIN EN.CITE ,. Briefly, the forward primer was designed on the boundary of exon 1 and 2 of the CYP21 genes, the reverse primer was located on c.332_339delGAGACTAC variant distinguishing CYP21A1P and CYP21A2 and the Taqman minor groove binder probe (Applied Biosystems) on the boundary of exon 2 and 3 was labeled with the fluorescent dye 6-FAM (Supplementary Table 1). Reactions were carried out in a 7500 Fast Real-Time PCR equipment by TaqMan Fast Advanced PCR master mix (Applied Biosystems). The human OAZ1 gene was used as an internal control27. Full-length CYP21 cDNA was amplified and cloned with primers designed for mRNA according to a previous study ADDIN EN.CITE 28. Briefly, CYP21A2 cDNA was amplified by Phusion DNA polymerase (New England Biolabs), the PCR product was directionally cloned into a pTZ57R vector, and subjected to Sanger sequencing. The methods of hormone measurements for NFAI patients and the software for statistics were recently described ADDIN EN.CITE 22.
Results
A unique haplotypic RCCX CNV structure with three segments, LBSASB, harboring two CYP21A2 gene copies and the c.955C>Tp.Q319* variant
The c.955C>T (p.Q319*) variant was detected in 7 healthy subjects out of 164 (allele frequency is 2.1%), in 5 NFAI patients out of 125 (2.0%), and in 6 classical CAH patients out of 100 patients (3.0%). To find out which haplotypic RCCX CNV structure and CYP21A2 haplotype harbor the c.955T allele, a set of molecular haplotyping methods ADDIN EN.CITE 1 were used for the experimental dissection in the first stage. Then the haplotypic information based on molecular haplotyping from the first stage, and the genotypic information of all studied healthy subjects and patients with NFAI were used for bioinformatic haplotype reconstruction in the second stage (see detailed description of how the experimental and bioinformatic methods work elsewhere ADDIN EN.CITE 1). The first, experimental stage revealed the following genetic features; i.) All the healthy subjects and all the NFAI patients who had the c.955T allele (12 individuals) carried a haplotypic RCCX CNV structure on one chromosome harboring 2 CYP21A2 gene copies (they had 3 CYP21A2 gene copies as a whole). ii.) The extra CYP21A2 gene copy in the 5’-segment or the middle segment of RCCX CNV was always related to a C4A gene in the 5’-direction, and the CYP21A2 haplotype of these segments could be determined in all 13 individuals (Figure 2A). Accordingly, two almost identical and unique (not observed in former studies ADDIN EN.CITE ,) CYP21A2 haplotypes were located in the 5’-segment or the middle segment, the h63 (in 1 individual) and h64 (in 11 individuals). iii.) From these 11 individuals with the h64 haplotype, the middle segment of a LBSASB RCCX structure harbored h64 in 2 individuals. iv.) Two individuals with c.955C>Tp.Q319* carried a suitable RCCX structure combination for the CYP21A2 haplotype determination in the 3’-segment (Figure 2B), and they had a unique, undescribed h65 CYP21A2 haplotype there. In addition, both CYP21A2 haplotypes in one haplotypic RCCX structure were also determined in a one-year-old CAH patient with c.955C>Tp.Q319*, whose DNA sample was received in order to re-examine the original genetic diagnosis based on parental genotypes, because the required dose of steroid substitution was unchanged in spite of weight gain. In this putative CAH patient, the 3’-segment also harbored a h65 haplotype, and a h64 haplotype was carried as a second CYP21A2 copy.
The second, bioinformatic stage resolved a unique LBSASB RCCX structure harboring very similar h63 or h64 CYP21A2 haplotypes in the middle segment and very similar h65, h66, h67 or h68 haplotypes in the 3’-segment above a 0.99 confidence probability threshold in all 12 individuals and the reexamined CAH patient (Figure 2C). A specific allele, c.*12T, occurred only in h63 and h64 haplotypes of the middle segment and not in any other haplotypes of healthy subjects and patients with NFAI, and a specific allele, c.293-79A, occurred only in h65-h68 haplotypes of the 3’-segment (Supplementary Table 2). Consequently, these two variants and c.955C>T have the same allele frequency as the LBSASB RCCX structure harboring them, they were in complete LD (r2=1), and, furthermore, there was no significant difference between the allele frequencies in healthy subjects and patients with NFAI (Fisher’s exact test, p=1.0000).
CYP21A2 haplotypes of classical CAH patients with c.955C>Tp.Q319*
In total, 7 CYP21A2 haplotypes with the c.955T allele (p.Q319*) were found in 6 patients out of the studied 100 patients with classical CAH (Table 3). The c.*12T allele did not occur in these 6 CAH patients, but the c.293-79A allele was observed in 3 patients. From the 7 haplotypes with the c.955T allele, 3 CYP21A2 haplotypes were experimentally determined; a h65 haplotype harbored by a LASA RCCX CNV structure, a haplotype (h69), which had an extended CYP21A1P sequence approximately from intron 6 to the 3’-end of the gene including c.955T, and a haplotype (h70), which did not harbor any alleles characterizing CYP21A1P apart from c.955T. Bioinformatic haplotype reconstruction can accurately resolve haplotypes when they recurrently occur in a studied population, but CYP21A2 haplotypes with CAH variants not determined by experiments did not satisfy this requirement. However, it was highly probable that a CYP21A2 haplotype (in patient 2) was identical with the h67 haplotype of LBSASB RCCX structure, and a haplotype (in patient 5) also had an extended CYP21A1P sequence at the 3’-end of the gene. Furthermore, the CYP21A2 haplotypes of CAH patients were not assigned to LBSASB or a chromosome harboring a second copy of CYP21A2, although the presence of the c.293-79A allele in classical CAH patients implied that the CYP21A2 haplotypes harboring c.293-79A had derived from the CYP21A2 in the 3’-segment of LBSASB.
Origin of CYP21A2 haplotypes with c.955C>Tp.Q319* in healthy and CAH individuals
To assess the evolutionary origin of CYP21A2 haplotypes, a genealogical (evolutionary) haplotype network was applied as described recently ADDIN EN.CITE 1. Briefly, haplotypes which are more similar to each other are located close to each other in the haplotype network, and are considered to be closer relatives29.
The CYP21A2 haplotypes (h63 and h64) in the middle segment of the LBSASB RCCX structure clustered together and were far from the group of the haplotypes (h65-h68) in the 3’-segment of LBSASB on the haplotype network (Figure 3A). This supports the idea that the haplotypes in each group were closely linked, but a distant relationship was observed between the two groups. The distant relationship implies that an unequal crossover event between two distantly related RCCX structures generated the LBSASB structure. However, the SB and LASB RCCX structure groups next to the RCCX structure assigned to h63-h64 and h65-h68 groups do not suggest a one-step mechanism for this structure generation. Nevertheless, a potential multi-step generation with unequal crossover or an alternative explanation of multiple non-allelic gene conversion events equally indicates a relatively ancient origin of the LBSASB structure. Not only the multi-step mechanism, but the presence of LBSASB-specific variants, also confirms this.
One experimentally determined CYP21A2 haplotype with the c.955T allele (p.Q319*) from classical CAH patients was in the haplotype group of the 3’-segment of the LBSASB, indicating a common descent. The LASA RCCX structure harboring the LBSASB-identical h65 haplotype was generated by simple (equal) or unequal crossover ADDIN EN.CITE , between LBSASB and existing RCCX structures in the studied population ADDIN EN.CITE ,. In the case of (equal) crossover, the breakpoint would have been after the C4A in the 3’-segments of the LASA structure and between the C4B and CYP21A2 in the 3’-segment of the LBSASB harboring the h65 haplotype (Figure 3B), while it would have been after the C4A in the middle segments of the LASALB structure and in the same place of the LBSASB structure in the case of unequal crossover. In both cases, the functional CYP21A2 in the middle segment of LBSASB vanished from the emerged LASA RCCX structure.
Two other experimentally determined CAH-causing CYP21A2 haplotypes with the c.955T allele (h69 and h70) were located separately from either haplotypes in LBSASB and from each other, supporting their independent origins from the LBSASB RCCX structure (probably by non-allelic gene conversions from the CYP21A1P of the same RCCX structure where c.955T occurs). The connections of these two CYP21A2 haplotypes to the stem of the haplotype network were confirmed by the harboring RCCX structures of the connected haplotypes (h69 harbored by LALB RCCX structure and h70 harbored by LASB RCCX structure).
Gene expression and function of CYP21A2 in the carriers of LBSASB RCCX structure with the c.955C>Tp.Q319* variant
LBSASB RCCX structure with the c.955T allele (p.Q319*) was observed in 1 out of 34 adrenocortical tumor specimens of patients with NFAI. The CYP21A2 mRNA level of this c.955C>Tp.Q319* carrier patient did not significantly differ (t-test, p=0.3312) from those of non-carrier patients (Figure 4A). Furthermore, this c.955C>Tp.Q319* carrier patient had an h64 CYP21A2 haplotype in the middle segment of LBSASB, an h65 haplotype in the 3’-segment, and an h28 haplotype in the SB RCCX structure of the other chromosome (the exact RCCX structures of this patient is actually shown in Figure 2A). The transcripts of these three CYP21A2 haplotypes harbored distinctive alleles on c.*12C>T and c.*52C>T variants; CC alleles for h65, CT alleles for h28 and TT alleles for h64 (Figure 4B). To ascertain the frequencies of the different transcripts derived from these three different CYP21A2 haplotypes, cDNA was generated from total mRNA, and the CYP21A2 transcripts were cloned and sequenced in five independent experiments. The h64 transcript was present, indicating that CYP21A2 in the middle segment was transcriptionally active. The h65 transcript was not detected, whereas the frequency of the h28 transcript from the other chromosome was significantly lower than that of the h64 transcript (Figure 4C). The hormone profiles of the carriers of LBSASB with c.955C>Tp.Q319* (N=5) and non-carriers (N=102) of NFAI patients from our recent study ADDIN EN.CITE 22 were compared, but no significant difference was detected in morning cortisol, midnight cortisol, adrenocorticotropic hormone (ACTH)-induced cortisol, morning aldosterone, ACTH-induced aldosterone, morning 17-OH-progesterone, morning corticosterone, ACTH-induced corticosterone, metyrapone-blocked 11-deoxycortisol, morning dehydroepiandrosterone sulfate, ACTH or metyrapone-blocked ACTH levels (Supplementary Table 4).
Discussion
A moderately frequent, unique haplotypic RCCX CNV structure with three segments harboring two CYP21A2 gene copies, abbreviated to LBSASB, was determined in 13 individuals (7 healthy subjects, 5 patients with NFAI and 1 reexamined CAH patient) with normal steroid levels by a set of experimental and bioinformatic methods published recently ADDIN EN.CITE ,. This set of methods is capable of not only a more exact determination of RCCX structure than some current methods, but also the segment-specific sequencing of CYP21A2: thus the haplotypes of the two harbored CYP21A2 in the middle and the 3’-segments of the RCCX CNV were revealed. The CYP21A2 haplotypes in the middle segment harbored the c.*12T allele, while the CYP21A2 haplotypes in the 3’-segment harbored the c.293-79A and c.955T (p.Q319*) alleles. Both c.293-79G>A and c.*12C>T variants are in complete LD with the c.955C>T variant in the healthy subjects of two European (Spanish and Italian) populations ADDIN EN.CITE ,, suggesting a straightforward usage of these variants to distinguish between pathogenic and non-pathogenic genomic contexts of the c.955C>T variant in the genetic diagnosis of CAH, but unfortunately there is no available information from c.293-79G>A and c.*12C>T in the CAH patients of these populations. Our findings on the healthy subjects and the patients with NFAI and CAH of the Hungarian population indicated that only the c.*12T allele is unique in the individuals with normal steroid hormone levels. Therefore, the genetic examination of c.*12C>T allows us to avoid the genetic misinterpretation of p.(Q319*).
The ability of the c.*12C>T to discriminate between CYP21A2 copies with c.955C>Tp.Q319* in non-pathogenic and pathogenic genomic contexts can be readily built into molecular diagnosis approaches ADDIN EN.CITE ,, which seems to be especially important for populations with high c.955C>Tp.Q319* frequency from North Africa and Asia ADDIN EN.CITE ,. Before its inclusion in the routine genetic diagnosis of CAH, the occurrence pattern of c.*12C>T should be investigated in both healthy subjects and CAH patients belonging to the target population. The pioneer study on c.955C>Tp.Q319* in RCCX structure with three segments and two CYP21A210 obviously illustrates the importance of validation in other populations: it is probable that the c.*12T and c.293-13G CAH alleles are simultaneously harbored in the middle segment in three CAH patients. However, the nationality and ancestry of these patients have not been documented, and thus a conclusion with regard to the origin of this RCCX structure unfortunately cannot be drawn.
Nevertheless, the three CAH-causing mutations in one patient harboring c.*12C>T implied that one of the mutations could occur in the CYP21A2 of the middle segment, disabling its functionality. Our evolutionary analysis provided a new insight into the underlying mechanism that generates such a clinical case. The CYP21A2 haplotypes with the c.955T allele are derived from the 3’-segment of the LBSASB RCCX structure or from CYP21A1P, according to the genealogical haplotype network. However, the second, functional copy of CYP21A2 in a chromosome was never carried by classical CAH patients with c.955C>T, independent of whether the c.955T allele of CYP21A2 haplotypes was derived from the 3’-segment of LBSASB or elsewhere. This putative rearrangement mechanism of CYP21A2 haplotypes with the c.955T derived from the LBSASB RCCX structure sheds light on why the c.*12T allele did not occur in Hungarian CAH patients carrying a CYP21A2 haplotype with c.293-79A and c.955T; if a rearranged RCCX structure loses the functional CYP21A2 from the middle segment of LBSASB, it will become pathogenic, and if a rearranged RCCX structure retains the functionally intact CYP21A2 with c.*12T from the middle segment, it will rescue its carrier from CAH. Nevertheless, it cannot be excluded that a rearrangement such as non-allelic gene conversion deletes or transfers the c.*12T allele from its original genomic context, or transfers a pathogenic mutation to CYP21A2 in the middle segment (the frequency of such an event will be very rare, because a rare event happens in the moderately frequent LBSASB). Therefore, careful consideration is always a basic requirement in the genetic diagnosis of CAH, and the sequencing of full-length CYP21A2 from the segment-specific PCR product of the middle segment is needed after the finding of the c.*12T allele in the extremely rare case when more than two CAH mutations (including c.955C>Tp.Q319*) are detected in one individual.
The significance of the c.955C>Tp.Q319* variant in the molecular diagnosis of CAH is testified by a recent case study on a misdiagnosed c.955C>Tp.Q319* variant ADDIN EN.CITE 36. This kind of case is not extremely rare, and there may be no better example of how true that is than one of our cases. The original genetic diagnosis of a one-year-old patient with classical CAH was reexamined, because the required dose of hormone substitution was unchanged in spite of weight gain. The father had a known history of classical CAH due to CYP21A2 deficiency and the healthy mother carried a c.955Tp.Q319* allele. The patient inherited the maternal c.955Tp.Q319* allele besides a paternal RCCX structure without CYP21A2, and was therefore treated with mineralocorticoids and glucocorticoids from birth. The reexamination demonstrated that an intact CYP21A2 was harbored by the middle segment of LBSASB next to the c.955C>Tp.Q319* variant in the 3’-segment. The steroid supplementation had been gradually reduced, and then completely discontinued based on this finding, without any clinical signs of adrenocortical insufficiency.
Several studies based on the normal steroid levels of subjects with two carried CAH variants have found indirect evidence proving that one of the two CYP21A2 associated with the c.955C>Tp.Q319* variant in one chromosome expresses active steroid 21-hydroxylase enzyme ADDIN EN.CITE 36-39. However, direct evidence for the functional CYP21A2 in the middle segment was provided by the current study for the first time. In the adrenal specimen of a patient with NFAI, the CYP21A2 in the middle segment of the LBSASB RCCX structure produced an mRNA transcript differing from the transcripts of the CYP21A2 copies in the 3’-segment and the other chromosome, and this middle segment-specific CYP21A2 transcript was detected. The CYP21A2 transcript from the middle segment was significantly more abundant than the other two transcripts, but neither CYP21A2 mRNA expression levels nor hormone levels in blood significantly differed between the LBSASB carriers and the non-carriers in NFAI patients. It should be noted that the quantitative analysis of the abundance of different CYP21A2 transcripts was not absolutely reliable because only one adrenal specimen was examined (however, we have no reason to question the existence of the CYP21A2 transcript expressed from the middle segment of LBSASB), and the sample size of NFAI patients was not sufficient for the detection of subtle hormonal differences in blood. In fact, several hundreds of adrenal specimens or NFAI patients should be examined to collect enough LBSASB carriers for the more reliable analyses on the abundance of CYP21A2 mRNAs or the subtle hormonal differences due to the moderate prevalence of LBSASB.
The current study is in tune with the results that have been presented so far (Table 2). In addition, the allele frequencies (around 1-2%) and the almost complete LD between c.293-79G>A and c.*12C>T in the European populations of the 1000 Genomes project ADDIN EN.CITE 40 also imply the presence of LBSASB RCCX structure. However, the next generation sequencing (NGS) based methods cannot reveal the exact internal content of multiallelic CNVs ADDIN EN.CITE 41, and the bioinformatic analysis of NGS data is still prone to errors42; hence c.*12C>T is documented by dbSNP as a variant of CYP21A2 in the 3’-segment. According to the current finding, the c.*12 nucleotide position is never polymorphic in the 3’-segment, but it is in the middle segment. Therefore, this phenomenon cannot be described by the traditional variant definition of non-duplicated genomic regions, and the usage of the variant categories for duplicated genes ADDIN EN.CITE , should be considered.
Acknowledgement
We are grateful to Mark Eyre for English proofreading, and the technical assistance of Andrea Juhász is gratefully acknowledged. We also would like to thank the staff of Biomi Kft, Dr. Adrienn Micsinai, Dr. Anita Mohr, Dr. Rita Sipos and Réka Szántó-Egész for help with sequencing. This study was supported by Technology Innovation Fund, National Developmental Agency (KTIA-AIK-2012-12-1-0010), and A. Patócs is the recipient of a ‘‘Lendulet’’ grant from the Hungarian Academy of Sciences.
Conflict of interest
The authors declare no conflict of interest.
References
1.	Banlaki Z, Szabo JA, Szilagyi A et al: Intraspecific evolution of human RCCX copy number variation traced by haplotypes of the CYP21A2 gene. Genome Biol Evol 2013; 5: 98-112.2.	Handsaker RE, Van Doren V, Berman JR et al: Large multiallelic copy number variations in humans. Nat Genet 2015; 47: 296-303.3.	Blanchong CA, Zhou B, Rupert KL et al: Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease. J Exp Med 2000; 191: 2183-2196.4.	Szilagyi A, Doleschall M, Fust G: Complement genes in the central region of the MHC; in: Mehra NK (ed): The HLA complex in biology and medicine: a resource book. New Delhi: Jaypee Brothers Medical Publishers, 2010, pp 135-158.5.	Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine reviews 2011; 32: 81-151.6.	White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine reviews 2000; 21: 245-291.7.	Cooper DN, Bacolla A, Ferec C, Vasquez KM, Kehrer-Sawatzki H, Chen JM: On the sequence-directed nature of human gene mutation: The role of genomic architecture and the local DNA sequence environment in mediating gene mutations underlying human inherited disease. Hum Mutat 2011; 32: 1075-1099.8.	New MI, Abraham M, Gonzalez B et al: Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci U S A 2013; 110: 2611-2616.9.	Wedell A: Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): implications for diagnosis, prognosis and treatment. Acta Paediatr 1998; 87: 159-164.10.	Wedell A, Stengler B, Luthman H: Characterization of mutations on the rare duplicated C4/CYP21 haplotype in steroid 21-hydroxylase deficiency. Human genetics 1994; 94: 50-54.11.	Witchel SS, Lee PA, Trucco M: Who is a carrier? Detection of unsuspected mutations in 21-hydroxylase deficiency. American journal of medical genetics 1996; 61: 2-9.12.	Janner M, Pandey AV, Mullis PE, Fluck CE: Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963insA using a new 3D model for the P450c21 protein. European journal of endocrinology / European Federation of Endocrine Societies 2006; 155: 143-151.13.	Mohamed S, El-Kholy S, Al-Juryyan N, Al-Nemri AM, Abu-Amero KK: A CYP21A2 gene mutation in patients with congenital adrenal hyperplasia. Molecular genetics report from Saudi Arabia. Saudi medical journal 2015; 36: 113-116.14.	Globerman H, Amor M, Parker KL, New MI, White PC: Nonsense mutation causing steroid 21-hydroxylase deficiency. J Clin Invest 1988; 82: 139-144.15.	Koppens PF, Hoogenboezem T, Degenhart HJ: CYP21 and CYP21P variability in steroid 21-hydroxylase deficiency patients and in the general population in the Netherlands. Eur J Hum Genet 2000; 8: 827-836.16.	Koppens PF, Hoogenboezem T, Degenhart HJ: Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes. Human genetics 2002; 111: 405-410.17.	Parajes S, Quinteiro C, Dominguez F, Loidi L: High frequency of copy number variations and sequence variants at CYP21A2 locus: implication for the genetic diagnosis of 21-hydroxylase deficiency. PLoS One 2008; 3: e2138.18.	Kleinle S, Lang R, Fischer GF et al: Duplications of the functional CYP21A2 gene are primarily restricted to Q318X alleles: evidence for a founder effect. The Journal of clinical endocrinology and metabolism 2009; 94: 3954-3958.19.	Szabo JA, Szilagyi A, Doleschall Z et al: Both positive and negative selection pressures contribute to the polymorphism pattern of the duplicated human CYP21A2 gene. PLoS One 2013; 8: e81977.20.	Young WF, Jr.: Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356: 601-610.21.	Banlaki Z, Doleschall M, Rajczy K, Fust G, Szilagyi A: Fine-tuned characterization of RCCX copy number variants and their relationship with extended MHC haplotypes. Genes and immunity 2012; 13: 530-535.22.	Doleschall M, Szabo JA, Pazmandi J et al: Common genetic variants of the human steroid 21-hydroxylase gene (CYP21A2) are related to differences in circulating hormone levels. PLoS One 2014; 9: e107244.23.	Luczay A, Torok D, Ferenczi A, Majnik J, Solyom J, Fekete G: Potential advantage of N363S glucocorticoid receptor polymorphism in 21-hydroxylase deficiency. European journal of endocrinology / European Federation of Endocrine Societies 2006; 154: 859-864.24.	Patocs A, Toth M, Barta C et al: Hormonal evaluation and mutation screening for steroid 21-hydroxylase deficiency in patients with unilateral and bilateral adrenal incidentalomas. European journal of endocrinology / European Federation of Endocrine Societies 2002; 147: 349-355.25.	Boyle B, Butz H, Liko I et al: Expression of glucocorticoid receptor isoforms in human adrenocortical adenomas. Steroids 2010; 75: 695-700.26.	Cervenak J, Doleschall M, Bender B et al: NFkappaB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn. mAbs 2013; 5: 860-871.27.	de Jonge HJ, Fehrmann RS, de Bont ES et al: Evidence based selection of housekeeping genes. PLoS One 2007; 2: e898.28.	Doleschall M, Mayer B, Cervenak J, Cervenak L, Kacskovics I: Cloning, expression and characterization of the bovine p65 subunit of NFkappaB. Dev Comp Immunol 2007; 31: 945-961.29.	Posada D, Crandall KA: Intraspecific gene genealogies: trees grafting into networks. Trends Ecol Evol 2001; 16: 37-45.30.	Chung EK, Yang Y, Rennebohm RM et al: Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex. American journal of human genetics 2002; 71: 823-837.31.	Concolino P, Mello E, Minucci A, Giardina B, Capoluongo E: Genes, pseudogenes and like genes: the case of 21-hydroxylase in Italian population. Clin Chim Acta 2013; 424: 85-89.32.	Tsai LP, Cheng CF, Chuang SH, Lee HH: Analysis of the CYP21A1P pseudogene: indication of mutational diversity and CYP21A2-like and duplicated CYP21A2 genes. Anal Biochem 2011; 413: 133-141.33.	Xu Z, Chen W, Merke DP, McDonnell NB: Comprehensive mutation analysis of the CYP21A2 gene: an efficient multistep approach to the molecular diagnosis of congenital adrenal hyperplasia. The Journal of molecular diagnostics : JMD 2013; 15: 745-753.34.	Kharrat M, Tardy V, M'Rad R et al: Molecular genetic analysis of Tunisian patients with a classic form of 21-hydroxylase deficiency: identification of four novel mutations and high prevalence of Q318X mutation. The Journal of clinical endocrinology and metabolism 2004; 89: 368-374.35.	Marumudi E, Sharma A, Kulshreshtha B, Khadgawat R, Khurana ML, Ammini AC: Molecular genetic analysis of CYP21A2 gene in patients with congenital adrenal hyperplasia. Indian journal of endocrinology and metabolism 2012; 16: 384-388.36.	Lekarev O, Tafuri K, Lane AH et al: Erroneous prenatal diagnosis of congenital adrenal hyperplasia owing to a duplication of the CYP21A2 gene. Journal of perinatology : official journal of the California Perinatal Association 2013; 33: 76-78.37.	Baumgartner-Parzer SM, Nowotny P, Waldhausl W, Vierhapper H: A rare duplicated 21-hydroxylase haplotype and a de novo mutation: a family analysis. The Journal of clinical endocrinology and metabolism 2003; 88: 2794-2796.38.	Kharrat M, Riahi A, Maazoul F, M'Rad R, Chaabouni H: Detection of a frequent duplicated CYP21A2 gene carrying a Q318X mutation in a general population with quantitative PCR methods. Diagnostic molecular pathology : the American journal of surgical pathology, part B 2011; 20: 123-127.39.	Leccese A, Longo V, Dimatteo C et al: Lack of genotypephenotype correlation in congenital adrenal hyperplasia due to a CYP21A2-like gene. Clin Chim Acta 2014; 437: 48-51.40.	Auton A, Brooks LD, Durbin RM et al: A global reference for human genetic variation. Nature 2015; 526: 68-74.41.	Nuttle X, Huddleston J, O'Roak BJ et al: Rapid and accurate large-scale genotyping of duplicated genes and discovery of interlocus gene conversions. Nat Methods 2013; 10: 903-909.42.	Li H: Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics 2014; 30: 2843-2851.43.	Innan H: Population genetic models of duplicated genes. Genetica 2009; 137: 19-37.
2.	Handsaker RE, Van Doren V, Berman JR et al: Large multiallelic copy number variations in humans. Nat Genet 2015; 47: 296-303.
3.	Blanchong CA, Zhou B, Rupert KL et al: Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease. J Exp Med 2000; 191: 2183-2196.
4.	Szilagyi A, Doleschall M, Fust G: Complement genes in the central region of the MHC; in: Mehra NK (ed): The HLA complex in biology and medicine: a resource book. New Delhi: Jaypee Brothers Medical Publishers, 2010, pp 135-158.
5.	Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine reviews 2011; 32: 81-151.
6.	White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine reviews 2000; 21: 245-291.
7.	Cooper DN, Bacolla A, Ferec C, Vasquez KM, Kehrer-Sawatzki H, Chen JM: On the sequence-directed nature of human gene mutation: The role of genomic architecture and the local DNA sequence environment in mediating gene mutations underlying human inherited disease. Hum Mutat 2011; 32: 1075-1099.
8.	New MI, Abraham M, Gonzalez B et al: Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci U S A 2013; 110: 2611-2616.
9.	Wedell A: Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): implications for diagnosis, prognosis and treatment. Acta Paediatr 1998; 87: 159-164.
10.	Wedell A, Stengler B, Luthman H: Characterization of mutations on the rare duplicated C4/CYP21 haplotype in steroid 21-hydroxylase deficiency. Human genetics 1994; 94: 50-54.
11.	Witchel SS, Lee PA, Trucco M: Who is a carrier? Detection of unsuspected mutations in 21-hydroxylase deficiency. American journal of medical genetics 1996; 61: 2-9.
12.	Janner M, Pandey AV, Mullis PE, Fluck CE: Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963insA using a new 3D model for the P450c21 protein. European journal of endocrinology / European Federation of Endocrine Societies 2006; 155: 143-151.
13.	Mohamed S, El-Kholy S, Al-Juryyan N, Al-Nemri AM, Abu-Amero KK: A CYP21A2 gene mutation in patients with congenital adrenal hyperplasia. Molecular genetics report from Saudi Arabia. Saudi medical journal 2015; 36: 113-116.
14.	Globerman H, Amor M, Parker KL, New MI, White PC: Nonsense mutation causing steroid 21-hydroxylase deficiency. J Clin Invest 1988; 82: 139-144.
15.	Koppens PF, Hoogenboezem T, Degenhart HJ: CYP21 and CYP21P variability in steroid 21-hydroxylase deficiency patients and in the general population in the Netherlands. Eur J Hum Genet 2000; 8: 827-836.
16.	Koppens PF, Hoogenboezem T, Degenhart HJ: Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes. Human genetics 2002; 111: 405-410.
17.	Parajes S, Quinteiro C, Dominguez F, Loidi L: High frequency of copy number variations and sequence variants at CYP21A2 locus: implication for the genetic diagnosis of 21-hydroxylase deficiency. PLoS One 2008; 3: e2138.
18.	Kleinle S, Lang R, Fischer GF et al: Duplications of the functional CYP21A2 gene are primarily restricted to Q318X alleles: evidence for a founder effect. The Journal of clinical endocrinology and metabolism 2009; 94: 3954-3958.
19.	Szabo JA, Szilagyi A, Doleschall Z et al: Both positive and negative selection pressures contribute to the polymorphism pattern of the duplicated human CYP21A2 gene. PLoS One 2013; 8: e81977.
20.	Young WF, Jr.: Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356: 601-610.
21.	Banlaki Z, Doleschall M, Rajczy K, Fust G, Szilagyi A: Fine-tuned characterization of RCCX copy number variants and their relationship with extended MHC haplotypes. Genes and immunity 2012; 13: 530-535.
22.	Doleschall M, Szabo JA, Pazmandi J et al: Common genetic variants of the human steroid 21-hydroxylase gene (CYP21A2) are related to differences in circulating hormone levels. PLoS One 2014; 9: e107244.
23.	Luczay A, Torok D, Ferenczi A, Majnik J, Solyom J, Fekete G: Potential advantage of N363S glucocorticoid receptor polymorphism in 21-hydroxylase deficiency. European journal of endocrinology / European Federation of Endocrine Societies 2006; 154: 859-864.
24.	Patocs A, Toth M, Barta C et al: Hormonal evaluation and mutation screening for steroid 21-hydroxylase deficiency in patients with unilateral and bilateral adrenal incidentalomas. European journal of endocrinology / European Federation of Endocrine Societies 2002; 147: 349-355.
25.	Boyle B, Butz H, Liko I et al: Expression of glucocorticoid receptor isoforms in human adrenocortical adenomas. Steroids 2010; 75: 695-700.
26.	Cervenak J, Doleschall M, Bender B et al: NFkappaB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn. mAbs 2013; 5: 860-871.
27.	de Jonge HJ, Fehrmann RS, de Bont ES et al: Evidence based selection of housekeeping genes. PLoS One 2007; 2: e898.
28.	Doleschall M, Mayer B, Cervenak J, Cervenak L, Kacskovics I: Cloning, expression and characterization of the bovine p65 subunit of NFkappaB. Dev Comp Immunol 2007; 31: 945-961.
29.	Posada D, Crandall KA: Intraspecific gene genealogies: trees grafting into networks. Trends Ecol Evol 2001; 16: 37-45.
30.	Chung EK, Yang Y, Rennebohm RM et al: Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex. American journal of human genetics 2002; 71: 823-837.
31.	Concolino P, Mello E, Minucci A, Giardina B, Capoluongo E: Genes, pseudogenes and like genes: the case of 21-hydroxylase in Italian population. Clin Chim Acta 2013; 424: 85-89.
32.	Tsai LP, Cheng CF, Chuang SH, Lee HH: Analysis of the CYP21A1P pseudogene: indication of mutational diversity and CYP21A2-like and duplicated CYP21A2 genes. Anal Biochem 2011; 413: 133-141.
33.	Xu Z, Chen W, Merke DP, McDonnell NB: Comprehensive mutation analysis of the CYP21A2 gene: an efficient multistep approach to the molecular diagnosis of congenital adrenal hyperplasia. The Journal of molecular diagnostics : JMD 2013; 15: 745-753.
34.	Kharrat M, Tardy V, M'Rad R et al: Molecular genetic analysis of Tunisian patients with a classic form of 21-hydroxylase deficiency: identification of four novel mutations and high prevalence of Q318X mutation. The Journal of clinical endocrinology and metabolism 2004; 89: 368-374.
35.	Marumudi E, Sharma A, Kulshreshtha B, Khadgawat R, Khurana ML, Ammini AC: Molecular genetic analysis of CYP21A2 gene in patients with congenital adrenal hyperplasia. Indian journal of endocrinology and metabolism 2012; 16: 384-388.
36.	Lekarev O, Tafuri K, Lane AH et al: Erroneous prenatal diagnosis of congenital adrenal hyperplasia owing to a duplication of the CYP21A2 gene. Journal of perinatology : official journal of the California Perinatal Association 2013; 33: 76-78.
37.	Baumgartner-Parzer SM, Nowotny P, Waldhausl W, Vierhapper H: A rare duplicated 21-hydroxylase haplotype and a de novo mutation: a family analysis. The Journal of clinical endocrinology and metabolism 2003; 88: 2794-2796.
38.	Kharrat M, Riahi A, Maazoul F, M'Rad R, Chaabouni H: Detection of a frequent duplicated CYP21A2 gene carrying a Q318X mutation in a general population with quantitative PCR methods. Diagnostic molecular pathology : the American journal of surgical pathology, part B 2011; 20: 123-127.
39.	Leccese A, Longo V, Dimatteo C et al: Lack of genotypephenotype correlation in congenital adrenal hyperplasia due to a CYP21A2-like gene. Clin Chim Acta 2014; 437: 48-51.
40.	Auton A, Brooks LD, Durbin RM et al: A global reference for human genetic variation. Nature 2015; 526: 68-74.
41.	Nuttle X, Huddleston J, O'Roak BJ et al: Rapid and accurate large-scale genotyping of duplicated genes and discovery of interlocus gene conversions. Nat Methods 2013; 10: 903-909.
42.	Li H: Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics 2014; 30: 2843-2851.





Scaled representation of the organization of human RCCX copy number variation (CNV) depicted by RCCX structures with one, two and three segments. Each segment (repeat) is abbreviated with two letters, the first represents the alleles of the HERV-K(C4) CNV (L – long (insertion) allele or S – short (deletion) allele), and the second symbolizes the types of C4 gene (A or B). The duplications of these two letters indicate RCCX structures with more than one segment. Dotted lines indicate the segment boundaries. The variable region of the RCCX with two segments contains two pairs of full-length genes, complement component 4 (C4A and C4B) and steroid 21-hydroxylase (CYP21A1P and CYP21A2. Other two gene pairs partially residing in RCCX CNV, TNXA-TNXB and STK19 and STK19P, are not illustrated.
Figure 2.
The experimental determination (molecular haplotyping) of haplotypic RCCX CNV structures, CYP21A2 haplotypes and the resultant CYP21A2 haplotypes of LBSASB RCCX structure. A-S ASLR-PCR indicates allele-specific long-range PCR only from the C4A gene in the 5’-segment or the middle segment, A-T ASLR-PCR indicates ASLR-PCR only from the C4A gene in the 3’-segment, and B-T ASLR-PCR indicates ASLR-PCR only from the C4B gene in the 3’-segment. Each haplotypic RCCX segment is abbreviated with two letters, the first represents the alleles of HERV-K(C4) CNV (L – long (insertion) allele or S – short (deletion) allele), and the second symbolizes the types of C4 gene (A or B). The multiplication of the two letters in a structure indicates the segment number. Other two gene pairs partially residing in RCCX CNV, TNXA-TNXB and STK19 and STK19P, are not illustrated. (A) The haplotypic RCCX structures and the CYP21A2 haplotype in the middle segment can be determined from the depicted diploid combination of the haplotypic RCCX structures, but the CYP21A2 haplotype in the 3’-segment cannot. (B) All CYP21A2 haplotypes can be determined from the depicted diploid combination of the haplotypic RCCX structures, because ASLR-PCR can separate the two 3’-segments from the different haploid copies of chromosome 6. (C) CYP21A2 haplotypes of the LBSASB RCCX structure. Only variants with at least moderate frequencies according to a recent study19 are presented. Specific genetic variants of these haplotypes are indicated by black triangles.
Figure 3.
Evolutionary processes of RCXX CNV structure harboring the c.955C>Tp.Q319* variant in CYP21A2. Each haplotypic RCCX segment is abbreviated with two letters, the first represents the alleles of HERV-K(C4) CNV (L – long (insertion) allele or S – short (deletion) allele), and the second symbolizes the types of C4 gene (A or B). The multiplication of the two letters in a structure indicates the segment number. (A) Genealogical haplotype networks of CYP21A2 haplotypes with projected haplotypic RCCX CNV structures. Numbers in gray circles indicate the known CYP21A2 haplotype, and numbers in orange, green and dark green circles represent the CYP21A2 haplotype published here for the first time. Orange circles indicate CYP21A2 haplotypes with the p.Q319* (c.955C>T) variant in classical CAH patients, green circles represent CYP21A2 haplotypes in the middle segment of the LBSASB RCCX structure, and dark green circles indicate CYP21A2 haplotypes with the c.955C>Tp.Q319* in the 3’-segment of LBSASB. The length of gray lines between the CYP21A2 haplotypes represents the nucleotide (allele) identity: greater length implies more different alleles between haplotypes and lower identity. (B) Both simple (equal) crossover between LASA and LBSASB RCCX structures and unequal crossover between LASALB and LBSASB structures could generate the LASA structure harboring a h65 CYP21A2 haplotype in the 3’-segment.
Figure 4.
The results of the functional studies on adrenocortical specimens of non-functioning adrenal incidentaloma (NFAI) patients. One asterisk indicates significant difference at p<0.05, whereas ns represents a non-significant difference, as calculated by a t-test. (A). CYP21A2 mRNA level in the adrenal specimens of c.955T allele (on LBSASB RCCX structure) p.Q319* carrier NFAI patient (N=1) and non-carrier patients (N=3). (B) The forward and reverse chromatogram of h28 and h64 transcripts from the c.955T allelep.Q319* carrier NFAI patient, where the distinctive alleles on c.*12C>T and c.*52C>T variants are indicated (CT alleles for h28 and TT alleles for h64). (C) The abundance of transcripts expressed from three CYP21A2 haplotypes (h28, h64 and h65) of the NFAI patient with c.955T allele on LBSASB RCCX structurep.Q319*.
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